Dehydration News and Research

Latest Dehydration News and Research

Muscle Flex develops a strong portfolio of 'Water' related products to maintain healthy lifestyle

Muscle Flex Inc. (www.MuscleFlexInc.com) announced today that it is developing a strong portfolio of "Water" related products to market using its direct response, online ecommerce and traditional retail methods. Muscle Flex® regards "Water" as potentially the most important ingredient in maintaining a healthy lifestyle and it is estimated that as much as 75% of Americans do not drink enough good clean water.

8 Oct 2009

Precautionary measures being taken at Texas hospitals for combating flu

Precautionary measures are being taken at hospital ERs across Texas in order to deal with record numbers of flu cases this season. According to a recent article on NBCDFW.com, hospital emergency rooms, including the one at Children's Medical Center of Dallas, are screening visitors for flu symptoms and not allowing children under 12 to be in the patient areas unless they are being treated.

8 Oct 2009

Napo Pharmaceuticals hosts educational panel to address global health and environment

Napo Pharmaceuticals, Inc. (Napo) recently hosted an educational panel to address the impact of the lack of access to clean water and enteric disease on global health, the environment, and human rights.

8 Oct 2009

EnWave files a patent application for nutraREV equipment in Canada

EnWave Corporation has received positive comments from the Patent Examiner with regard to the Company's Patent Co-Operation Treaty ("PCT") patent application for nutraREVTM equipment concept and use, leading the Company to believe that a favorable International Preliminary Report on Patentability ("IPRP") is forthcoming.

7 Oct 2009

FOLOTYN available for commercial sale in the United States

Allos Therapeutics, Inc. today announced that FOLOTYN (pralatrexate injection) is now available for commercial sale in the United States. The U.S. Food and Drug Administration (FDA) granted accelerated approval for FOLOTYN for use as a single agent for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) on September 24, 2009. This indication is based on overall response rate.

6 Oct 2009

Baxter launches HYLENEX recombinant for pediatric rehydration at the 2009 ACEP

Baxter International Inc. today announced the commercial launch of HYLENEX recombinant (hyaluronidase human injection) for use in pediatric rehydration at the 2009 American College of Emergency Physicians (ACEP) scientific assembly (Boston). HYLENEX, an enzyme, allows fluids to be administered under the skin (subcutaneously) rather than through a vein.

From Baxter International Inc. 5 Oct 2009

Research study suggests possibility of safely expanding donor kidney pool by 10 to 15 percent

Kidneys recovered from deceased donors with acute renal failure (ARF) - once deemed unusable for transplant - appear to work just as well as kidneys transplanted from deceased donors who do not develop kidney problems prior to organ donation, according to a new study by researchers at Wake Forest University Baptist Medical Center.

3 Oct 2009

Researchers screen decades-old frozen infant stool samples to detect norovirus

A search through decades-old frozen infant stool samples has yielded rich dividends for scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

3 Oct 2009

EnWave receives R&D funding to develop REV dehydration technologies

EnWave Corporation (TSX VENTURE:ENW)(FRANKFURT:E4U) ("EnWave" or "the Company") today announced that it has received research and development funding from three separate Canadian federal and provincial government agencies totaling $370,000 to continue the Company's development of its Radiant Energy Vacuum ("REV") dehydration technology for food, food cultures, and biopharmaceuticals.

30 Sep 2009

NIH awards DiscoveryBioMed a Phase 2 SBIR grant for research on hypertension and cystic fibrosis

DiscoveryBioMed, Inc. (DBM) today announced that it has been awarded a $750,000 Small Business Innovations Research (SBIR) Phase 2 grant by the National Institutes of Health (NIH) to continue the research into the discovery and development of small molecules to alleviate multiple chronic human diseases including cystic fibrosis (CF), hypertension and chronic kidney diseases with hypertension.

28 Sep 2009

Safety profiles of JANUVIA and JANUMET drugs established through clinical development program

Merck has thoroughly reviewed the safety data for sitagliptin, and sitagliptin was not associated with an increase in the incidence of pancreatitis in preclinical studies or in clinical trials of up to two years in duration with more than 6,000 patients.

28 Sep 2009

FDA grants accelerated approval for Allos Therapeutics’ FOLOTYN

Allos Therapeutics, Inc. (Nasdaq:ALTH) today announced that last night the U.S. Food and Drug Administration (FDA) granted accelerated approval for FOLOTYNTM (pralatrexate injection) for use as a single agent for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

28 Sep 2009

European CHMP recommends Merck's JANUVIA and JANUMET as add-on to insulin

Merck & Co., Inc., which operates in many countries as Merck Sharp & Dohme (MSD), has received a positive opinion from the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) for JANUVIA® tablets and JANUMET® tablets recommending their use as add-on to insulin for the treatment of type 2 diabetes.

26 Sep 2009

Three antibodies dried using EnWave's freezeREV vial dehydration technology

EnWave Corporation ("EnWave" or "the Company") today announced that it has successfully dried three different antibodies in the Company's prototype freezeREV vial dehydration technology.

25 Sep 2009

Millennium's sNDA for VELCADE granted priority review by the FDA

Millennium: The Takeda Oncology Company today announced that the U.S. Food and Drug Administration (FDA) has granted priority review to the Company’s supplemental new drug application (sNDA) for VELCADE. The sNDA contains long-term overall survival (OS) data from the landmark VISTA trial examining the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).

19 Sep 2009

EnWave signs Confidentiality Agreements with food production companies

EnWave Corporation (TSX VENTURE:ENW)(FRANKFURT:E4U) ("EnWave" or "the Company") today announced that it has signed Confidentiality Agreements with more than 15 food production companies located in North and South America, Europe and Korea to determine the benefits of using its nutraREVTM food dehydration technology in a wide range of new product areas including herbs, mushrooms, bananas, mangos, pineapples, peppers, tomatoes, garlic, snack chips, shrimp, salmon and pet treats.

17 Sep 2009

Medicare Advantage's preventive health care strategy keeps seniors out of the hospital

Seniors in Medicare Advantage spent fewer days in a hospital, were subject to fewer hospital re-admissions, and were less likely to have "potentially avoidable" admissions, for common conditions ranging from uncontrolled diabetes to dehydration, according to a new analysis of publicly available AHRQ data released today by America's Health Insurance Plans (AHIP).

16 Sep 2009

Merck update on the status of telcagepant clinical development programs

Merck & Co., Inc. today updated the status of the clinical development programs for telcagepant (MK-0974) and MK-3207, the Company's investigational oral calcitonin gene-related peptide (CGRP) receptor antagonists for the intermittent treatment of acute migraine.

11 Sep 2009

DOR's Phase 1/2 clinical trial for prevention of radiation enteritis receives NIH grant

DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biotechnology company, announced today that the National Institutes of Health (NIH) has awarded DOR a Small Business Innovation Research (SBIR) grant to support the conduct of a Phase 1/2 clinical trial evaluating DOR201, a time-release formulation of oral beclomethasone dipropionate (oral BDP), for the prevention of acute radiation enteritis.

8 Sep 2009

Millennium's sNDA to be reviewed by the FDA

The Takeda Oncology Company today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s supplemental new drug application (sNDA) based on long- term overall survival (OS) data from the landmark VISTA1 trial examining the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).

3 Sep 2009